Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

Oral Cavity Squamous Cell Carcinoma Clinical Trial

Official title: A Phase I/IIa, Single-Arm, Dose-Confirmation and Dose-Expansion Study Evaluating Changes in the Oral Microbiome of Patients With Oral Cavity Squamous Cell Carcinoma (OSCC) After Short-Term Ingestion of Nisin, a Naturally Occurring Food Preservative

Status Recruiting

Clinical Trial Summary

This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of California, San Francisco (UCSF).

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To demonstrate the tolerability of nisin administration, as assessed by the maximum tolerated dose (MTD) of nisin (Phase I).

II. To demonstrate the feasibility of nisin administration, as assessed by the treatment completion rate (Phase IIa).

SECONDARY OBJECTIVES:

I. To evaluate the safety of nisin administration, as assessed by the frequency and severity of adverse events (CTCAE v5.0) (Phase I).

II. To evaluate externally measured changes in primary and nodal tumor size on intraoral examination from baseline to time of surgery, as assessed by cross-sectional measurement of tumors/ulceration with calipers during dental exam (Phase IIa).

III. To evaluate clinical changes in periodontal condition on dental examination over the study period, as assessed according to the American Academy of Periodontology grading system (Phase IIa).

EXPLORATORY OBJECTIVES:

I. To characterize nisin-induced changes in oral microbiome population structure and function, and nisin sensitivity among key oral bacterial species.

II. To characterize inflammatory and anti-tumor cellular responses to nisin in the oral cancer environment.

III. To confirm the half-life and urinary excretion profile of nisin (Phase 1).

IV. To demonstrate the preliminary efficacy of nisin administration, as assessed by relapse-free survival (RFS) and overall survival (OS) (Phase IIa).

OUTLINE:

Participants receiving treatment at UCSF will be initially assigned to the Phase 1 dose finding arm. After an interim analysis is completed, enrollment into Phase IIa will begin at the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Participants will be treated for two weeks before planned surgery, complete OSCC resection surgery (standard of care, non-interventional) and will continue treatment for 6 additional months post-surgery. Follow-up will continue for 12 months after surgery. ;

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Oral Cavity Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck

• NCT number: NCT06097468
• Study type: Interventional
• Source: University of California, San Francisco
• Contact: Angelica Valadez
• Phone: 415-502-1879
• Email: Angelica.Valadez@ucsf.edu
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: February 2, 2024
• Completion date: September 1, 2027